ImmunityBio, Inc.
Tremor tracks 13 of its cancer trials.
Company-wide warning signs
These add points to every one of this company's trials.
Trials
- IBRXImmunityBio, Inc.10Calm
Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer
Running, no new patientsPhase 2328 patientsMain results: Oct 13, 2025 - IBRXImmunityBio, Inc.10Calm
HCW9218 for Advanced Pancreatic Cancer
FinishedPhase 1/221 patientsMain results: Feb 15, 2025 - IBRXImmunityBio, Inc.10Calm
QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer
Running, no new patientsPhase 2/3190 patientsMain results: Oct 1, 2024 - IBRXImmunityBio, Inc.0Calm
Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy
Signing up patientsPhase 3507 patientsMain results: Sep 2028 - IBRXImmunityBio, Inc.0Calm
A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer
Signing up patientsPhase 220 patientsMain results: May 2027 - IBRXImmunityBio, Inc.0Calm
N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma
Running, no new patientsPhase 234 patientsMain results: Dec 31, 2029 - IBRXImmunityBio, Inc.0Calm
Phase 2 Study of NAI, HPV Vaccine, and Nab-Paclitaxel in HPV-Positive Oropharyngeal Cancer Followed by De-Intensified Radiation Compared With Standard Chemoradiation
Not started yetPhase 270 patientsMain results: Dec 31, 2030 - IBRXImmunityBio, Inc.0Calm
Study of Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma
Signing up patientsPhase 220 patientsMain results: May 25, 2027 - IBRXImmunityBio, Inc.0Calm
A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer
Running, no new patientsPhase 1/2369 patientsMain results: Sep 30, 2026 - IBRXImmunityBio, Inc.0Calm
ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG
Signing up patientsPhase 1/240 patientsMain results: Feb 2028 - IBRXImmunityBio, Inc.0Calm
Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin Lymphoma
Not started yetPhase 220 patientsMain results: Dec 2027 - IBRXImmunityBio, Inc.0Calm
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
Running, no new patientsPhase 240 patientsMain results: Aug 31, 2029 - IBRXImmunityBio, Inc.0Calm
Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer
Not started yetPhase 220 patientsMain results: Nov 2026
Key executives leaving
From the last 12 months of the company's SEC reports.
Insider trades (last 6 months)
“Insiders” are executives, board members, and big shareholders. Many of their sales are pre-planned: scheduled months ahead under a legal plan (called 10b5-1), so they usually say little. Tremor only counts sales that weren't pre-planned.
8 sales (0 not pre-planned) · 0 purchases
- Simon Barry J.Board member · Oct 5, 2026Sold 25,000 sharesabout $269 thousand · pre-planned
- Cohen CherylBoard member · Oct 2, 2026Sold 81,056 sharesabout $851 thousand · pre-planned
- Cohen CherylBoard member · Jul 2, 2026Sold 131,210 sharesabout $1.2 million · pre-planned
- Selecky ChristobelBoard member · Jul 1, 2026Sold 159,478 sharesabout $1.4 million · pre-planned
- Selecky ChristobelBoard member · Jun 30, 2026Sold 1,000 sharesabout $9 thousand · pre-planned
- Selecky ChristobelBoard member · Jun 29, 2026
Recent SEC filings
Public companies must report important news and their finances to the SEC, the US agency that oversees the stock market.